Oncologists

blood pressure gauge

Comorbidities Common in Patients With Advanced SM Prior to Diagnosis

Researchers reported that patients with newly diagnosed advanced systemic mastocytosis (SM) had high rates of comorbidities and healthcare service utilization prior to a confirmed diagnosis, according to a study published in Clinical Lymphoma, Myeloma & Leukemia. Advanced SM is a rare disorder caused by the KIT D816V mutation. It encompasses aggressive SM, mast cell leukemia,…

MTC

Case Report: MTC Responds to Treatment With Pralsetinib

Metastatic medullary thyroid carcinoma (MTC) with somatic variants of unknown significance in the RET gene can respond to treatment with pralsetinib, according to a recently published case report in the European Thyroid Journal. The case involved a 48-year-old man with liver metastases that were identified during a cholecystectomy. Computer tomography and magnetic resonance imaging revealed a primary…

Capsules

Selpercatinib Induces Durable and Sustained Responses in Patients With MTC

Patients with medullary thyroid carcinoma (MTC) treated with selpercatinib continue to show very durable responses in the phase1/2 LIBRETTO-001 clinical trial, according to an update published in the Annals of Oncology. This is the case whether or not they have received previous treatment with cabozantinib and vandetanib. These findings, which are based on additional patients…

physician patient form

Advanced SM Initially Presents With a Wide Range of Symptoms, Complicating Diagnosis

A new study has characterized the symptomatology of patients with advanced systemic mastocytosis (SM) as reported by oncologists at the first patient visit. The study, published in Clinical Lymphoma, Myeloma & Leukemia, found a wide range of symptoms, comorbid conditions, and diagnostic strategies for these patients. “Although driven by KIT D816V in 95% of cases,…

systemic mastocytosis therapies

Durvalumab Appears to Improve Survival in CCA

Results from the TOPAZ-1 phase 3 clinical trial suggest that durvalumab (Imfinzi®) combined with chemotherapy could increase overall survival in patients with biliary tract malignancies, including cholangiocarcinoma (CCA), according to a recently published press release. The trial results indicated that the combination of durvalumab and gemcitabine plus cisplatin can increase overall survival in patients with biliary…

GIST

Neoadjuvant Imatinib Linked With Better Surgical Outcome in Rectal GIST

Neoadjuvant treatment with imatinib could help make huge and low-lying rectal gastrointestinal stromal tumor (GIST) operable and lead to better surgical outcomes, according to a new study published in PLoS One. Rectal GIST is very rare, comprising 5% of all GISTs, which are rare themselves. However, rectal GIST has the worst prognosis and a recurrence…

Photodynamic therapy research in lab

Photodynamic Therapy Linked With Increased Survival in Cholangiocarcinoma

Percutaneous transhepatic cholangioscopy (PTCS)-guided photodynamic therapy (PDT) appears to increase survival and improve overall quality of life in patients with postoperative cholangiocarcinoma (CCA) recurrence, according to an article recently published in Photodiagnosis and Photodynamic Therapy. Although surgical resection is the preferred treatment for CCA, the majority of patients have advanced disease at the time of diagnosis…

Doctor viewing MRI brain scans

MEGNA Scoring System Insufficient in Assessing Survival in CCA

Tumor multifocality, extension, grade, lymph node involvement, and age (MEGNA), a prognostic scoring system, may not be enough to assess overall survival and disease-free survival in patients with cholangiocarcinoma (CCA), according to a retrospective study. The findings showed that the MEGNA score (c‐index=0.60) was similar to the frequently used tumor burden score (TBS; c‐index=0.58) and…

Immunotherapy

Dual-Agent Immunotherapy May Effectively Treat Refractory Cholangiocarcinoma

Sequential immunotherapy may be beneficial for patients with cholangiocarcinoma (CCA), although its indications are still unclear, according to a case series study recently published in the American Journal of Clinical Oncology. “This study can also serve as the foundation to build further tests on the true effectiveness and ideal duration of sequential therapy with dual immunotherapy…

Next post in CCA News Briefs